MA40228A - Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser - Google Patents

Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser

Info

Publication number
MA40228A
MA40228A MA040228A MA40228A MA40228A MA 40228 A MA40228 A MA 40228A MA 040228 A MA040228 A MA 040228A MA 40228 A MA40228 A MA 40228A MA 40228 A MA40228 A MA 40228A
Authority
MA
Morocco
Prior art keywords
methods
recombinant listeria
fusion proteins
heterologous antigen
listeria strain
Prior art date
Application number
MA040228A
Other languages
English (en)
Inventor
Don J Diamond
Joshua Ellenhorn
Robert Petit
Anu Wallecha
Original Assignee
Advaxis Inc
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc, Hope City filed Critical Advaxis Inc
Publication of MA40228A publication Critical patent/MA40228A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y501/00—Racemaces and epimerases (5.1)
    • C12Y501/01—Racemaces and epimerases (5.1) acting on amino acids and derivatives (5.1.1)
    • C12Y501/01001—Alanine racemase (5.1.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des acides nucléiques recombinés codant pour des antigènes tumoraux fusionnés à des polypeptides immunogènes et des souches de listéria recombinées les comprenant, des procédés pour les préparer, et des procédés pour induire une réponse immunitaire, et pour traiter, inhiber ou supprimer un cancer ou des tumeurs comprenant l'administration de celles-ci.
MA040228A 2014-07-18 2015-07-17 Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser MA40228A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462026085P 2014-07-18 2014-07-18

Publications (1)

Publication Number Publication Date
MA40228A true MA40228A (fr) 2017-05-24

Family

ID=55079085

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040228A MA40228A (fr) 2014-07-18 2015-07-17 Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser

Country Status (12)

Country Link
US (1) US20170246273A1 (fr)
EP (1) EP3169356A4 (fr)
JP (1) JP2017522027A (fr)
KR (1) KR20170028363A (fr)
CN (1) CN107073094A (fr)
AU (1) AU2015289529A1 (fr)
CA (1) CA2955366A1 (fr)
IL (1) IL249903A0 (fr)
MA (1) MA40228A (fr)
MX (1) MX2017000838A (fr)
SG (1) SG11201700092XA (fr)
WO (1) WO2016011353A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP2683400A4 (fr) 2011-03-11 2014-09-17 Advaxis Adjuvants à base de listeria
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
SG11201606677XA (en) 2014-02-18 2016-09-29 Advaxis Inc Biomarker directed multi-target immunotherapy
SG11201608820WA (en) 2014-04-24 2016-11-29 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
JP7197481B2 (ja) 2016-11-30 2022-12-27 アドバクシス， インコーポレイテッド 反復性がん突然変異を標的とする免疫原性組成物およびその使用の方法
US10372132B2 (en) 2016-12-12 2019-08-06 Apple Inc. Guidance of autonomous vehicles in destination vicinities using intent signals
WO2019060115A1 (fr) 2017-09-19 2019-03-28 Advaxis, Inc. Compositions et procédés de lyophilisation de bactéries ou de souches de listeria
EP3707152A4 (fr) * 2017-11-08 2021-12-01 Advaxis, Inc. Peptides hétéroclitiques immunogènes issus de protéines associées au cancer et procédés d'utilisation de ces peptides
WO2019157098A1 (fr) * 2018-02-06 2019-08-15 Advaxis, Inc. Compositions comprenant une souche de listeria recombinante et un anticorps anti-ccr8 et méthodes d'utilisation
EP3762719A1 (fr) * 2018-03-09 2021-01-13 Advaxis, Inc. Compositions et méthodes d'évaluation d'atténuation et d'infectivité de souches de listeria
SG10201901828TA (en) * 2019-02-28 2020-09-29 Nat Univ Singapore Recombinant bacteria and uses thereof
CN110607267B (zh) * 2019-09-25 2021-06-22 四川大学 一种绵羊李斯特菌平衡致死系统、构建方法及应用
CN114561417B (zh) * 2022-04-27 2022-08-09 中国科学院天津工业生物技术研究所 用于制备阿洛酮糖的谷氨酸棒杆菌工程菌株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100424096C (zh) * 2005-06-16 2008-10-08 华东理工大学 含有hiv转导结构域的生存素突变体及制备方法和应用
ES2741730T3 (es) * 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US20120135033A1 (en) * 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
EP2683400A4 (fr) * 2011-03-11 2014-09-17 Advaxis Adjuvants à base de listeria

Also Published As

Publication number Publication date
KR20170028363A (ko) 2017-03-13
MX2017000838A (es) 2017-09-01
JP2017522027A (ja) 2017-08-10
WO2016011353A1 (fr) 2016-01-21
US20170246273A1 (en) 2017-08-31
CA2955366A1 (fr) 2016-01-21
SG11201700092XA (en) 2017-02-27
EP3169356A4 (fr) 2018-03-28
AU2015289529A1 (en) 2017-02-09
EP3169356A1 (fr) 2017-05-24
IL249903A0 (en) 2017-03-30
CN107073094A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
MA40228A (fr) Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser
MA39849A (fr) Souches de listeria utilisées comme vaccin recombinant et procédé de production
MX2017008187A (es) Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr.
MX2017000836A (es) Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales.
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
MX2023002858A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
MX2016010565A (es) Inmunoterapia del cancer a través de la combinacion de estimulacion inmunatoria local y sistemica.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2021001098A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
MY193497A (en) Anti-myostatin antibodies and methods of use
MX2016011537A (es) Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras.
PH12019500591A1 (en) Canine adenovirus vectors
MX2020004829A (es) Péptidos heteroclíticos inmunogénicos de proteínas asociadas al cáncer y métodos de uso de los mismos.
MX2014009845A (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
MX2022007902A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
IL258004A (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
AR110730A1 (es) Vacunas de cepas recombinantes de listeria y método para usarlas en inmunoterapia de cáncer
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
WO2019006401A3 (fr) Compositions immunogènes à base de listeria comprenant des antigènes de protéine tumorale de wilms hétéroclitique et procédés d'utilisation correspondants
NZ742663A (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
HK1248610A1 (zh) 包含經修飾的α病毒表面糖蛋白與腫瘤相關抗原的融合蛋白及其方法
MX2018006347A (es) Proteinas de fusion fmdv y e2 y usos de ellos.